As indicated by IMS, Harvoni medicines add up to 7,513 amid the week finished Aug. 28, while new remedies fell 5% to 2,742. Joined with Sovaldi, downright hepatitis-C remedies fell 1% to 9,163, while new medicines declined 5% to 3,311.
Yee gauges that U.S. hepatitis-C deals ought to come in at around $12.1 billion in 2015, equitable underneath the accord for $12.4 billion. Still, that is superior to anything it was on August 13.
Shares of Gilead Sciences have increased 0.6% to $102.50 at 11:56 a.m. today, even as the iShares Nasdaq Biotechnology ETF (IBB) has plunged 0.1% to $338.18.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.